Janssen Search
Search results
The Potential of Biomarkers in Oncology Drug Development
Article Type: Oncology Realizing the Potential of Biomarkers in Oncology Drug Development It’s a real paradox: As of March 2014, there were more than 31,850 biomarkers listed in the GOBIOM database (GVK BIO Online Biomarker Database), but only 32 valid ...
Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting
Oct 03, 2023 United States Click to Access Audio Press Release Five abstracts to be presented, including new real-world research and data on Janssen’s investigational gene therapy JNJ-1887 RARITAN, N.J., October 3, 2023 – The Janssen Pharmaceutical ...
New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
Mar 04, 2023 United States Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
May 03, 2024 Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery SAN ANTONIO, May 3, ...
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
Jan 18, 2023 The Netherlands Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV No vaccine-related safety issues identified LEIDEN, THE NETHERLANDS, (January 18, 2023) – The ...
Recognizing World Arthritis Day 2017
Recognizing World Arthritis Day 2017 For more than three decades, Janssen Immunology has been focused on innovating for patients, because we understand the impact rheumatic diseases have on individuals, and their families, friends and loved ones. The ...
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
Jan 24, 2024 United States Clinical and real-world evidence data support treatment with ERLEADA ® (apalutamide) and niraparib plus abiraterone acetate given with prednisone in patients with prostate cancer Additional updates will be presented on ...
Gestational Diabetes Mellitus
Article Block Text: Using predictive biomarkers and monitoring to intervene pre-conception through pregnancy. Article Type: Disease Interception Accelerator Gestational Diabetes Mellitus Identification of women at risk through epidemiological modeling ...
Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Apr 21, 2023 United States Click to Access Audio Press Release Important new data on Janssen’s investigational gene therapy portfolio, including botaretigene sparoparvovec (bota-vec) and JNJ-1887, will be presented RARITAN, N.J., April 21, 2023 – The ...
Johnson & Johnson Neuroscience R&D Newsroom
OUR COMMITMENT TO NEUROPSYCHIATRIC, NEURODEGENERATIVE DISEASES AND NEUROSCIENCE AUTOANTIBODY DISEASES Thank you for visiting the Johnson & Johnson Neuroscience R&D Newsroom! Below, please find our meeting news, social feeds, and more information ...